NBIX
NASDAQ · Biotechnology
Neurocrine Biosciences Inc
$163.41
+3.59 (+2.25%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+18.71%
1Y
+31.80%
YTD
+16.22%
Open$161.53
Previous Close$159.82
Day High$164.76
Day Low$159.68
52W High$186.12
52W Low$122.14
Volume—
Avg Volume1.67M
Market Cap16.66B
P/E Ratio23.61
EPS$6.82
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$139.44
Above
SMA 200
$135.94
Above
RSI (14)
38.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
36 analysts
Price Target
-22.3% upside
Current
$163.41
$163.41
Target
$126.93
$126.93
$104.30
$126.93 avg
$177.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.84B | 2.29B | 5.53B |
| Net Income | 475.97M | 344.57M | 497.45M |
| Profit Margin | 16.7% | 15.9% | 9.0% |
| EBITDA | 641.55M | 490.25M | 909.27M |
| Free Cash Flow | — | — | 422.12M |
| Rev Growth | +24.3% | +24.3% | -8.7% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |